General Information of Drug (ID: DMX6QMT)

Drug Name
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
Synonyms 2-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile; 2-Anilino-5-aryloxazole 8; AC1NS7QZ; CHEMBL193912; BDBM5847; N-(2-Cyanophenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 261.279
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C16H11N3O
IUPAC Name
2-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile
Canonical SMILES
C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC=C3C#N
InChI
InChI=1S/C16H11N3O/c17-10-13-8-4-5-9-14(13)19-16-18-11-15(20-16)12-6-2-1-3-7-12/h1-9,11H,(H,18,19)
InChIKey
FPMCYJLZCOBPEC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5329843
TTD ID
D03HQK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [1]
Vascular endothelial growth factor receptor 3 (FLT-4) TTDCBX5 VGFR3_HUMAN Inhibitor [1]
VEGFR1 messenger RNA (VEGFR1 mRNA) TT1VAUK VGFR1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 1.98E-01 0.11 0.2
Vascular endothelial growth factor receptor 3 (FLT-4) DTT FLT4 6.00E-01 -0.04 -0.23
VEGFR1 messenger RNA (VEGFR1 mRNA) DTT FLT1 1.64E-05 0.29 0.51
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.